Related Experiment Video
Updated: Oct 5, 2025

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol
Published on: March 25, 2020
Niemann-Pick C1-Like 1 inhibitors for reducing cholesterol absorption
Renshuai Zhang1, Wenjing Liu1, Jun Zeng1
1The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266071, China; Cancer Institute, Qingdao University, Qingdao, 266071, China.
Abstract:
Cholesterol is an important component of cell membrane. However, elevated level of serum cholesterol is a key risk factor for heart disease. Niemann-Pick C1-Like 1 (NPC1L1) is the crucial target involving in cholesterol cellar uptake. Ezetimibe is the first, and only, NPC1L1 inhibitor approved for the treatment of hypercholesterolemia through decreasing cholesterol absorption for nearly two decades. That means that the development of NPC1L1 inhibitors encounters much challenge, as well as offers exciting therapeutic opportunities. Substantial efforts have been undertaken to develop NPC1L1 inhibitors. The present review describes the mechanism of cholesterol transport by NPC1L1, highlights the development of NPC1L1 inhibitors, and discusses the current challenges.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Drugs for Treatment of Constipation-Predominant IBS
Bioavailability Enhancement: Drug Permeability Enhancement
Cholesterol: Significance and Regulation
Considering cholesterol and...

